U.S. flag An official website of the United States government
  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. Huvepharma Inc - 01/30/2017
  1. Warning Letters


Huvepharma Inc

Huvepharma Inc

United States

Issuing Office:

United States



Black HHS-Blue FDA Logo



Kansas City District Office
8050 Marshall Drive - Suite 205
Lenexa, Kansas 66214-1524

January 30, 2017


Glen Wilkinson
Huvepharma, Inc.
525 West Park Dr., Suite 230
Peachtree City, GA 30269

Dear Mr. Wilkinson:

The Food and Drug Administration has completed an evaluation of your firm’s corrective actions in response to our Warning Letter [Ref. – 2013-10, June 13, 2013], follow-up inspections dated June 3-July 2, 2014, August 17-September 1, 2015, and October 6-26, 2016, and meetings dated October 15, 2014 and February 29, 2016. Based on our evaluation, it appears that you have addressed the violations contained in the Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.

This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.


Cheryl A. Bigham
District Director
Kansas City District

Brandon Clough, Quality Director
Huvepharma, Inc.
3360 Maury Ave
Saint Louis, MO 63116-2029 

Back to Top